What is Health2Sync?
Health2Sync is a provider of data-driven digital therapeutics and personalized healthcare management services, focusing on patients with chronic diseases, particularly diabetes. Their platform, accessible via a user-friendly mobile app, allows individuals to monitor health metrics and engage with healthcare professionals. The company's services include personalized reminders and tailored guidance, empowering users to actively manage their health and improve long-term outcomes. Health2Sync emphasizes secure healthcare services, adhering to ISO standards for information security, positioning itself as a reliable partner in chronic disease management.
How much funding has Health2Sync raised?
Health2Sync has raised a total of $30.5M across 4 funding rounds:
Angel/Seed
$1.5M
Series A
$3M
Series B
$6M
Series C
$20M
Angel/Seed (2014): $1.5M, investors not publicly disclosed
Series A (2016): $3M led by SparkLabs Global Ventures, iSeed Ventures, WI Harper Group, and Cherubic Ventures
Series B (2017): $6M supported by Sompo Holdings, WI Harper, and Alibaba.com
Series C (2025): $20M featuring Abies Capital, Taiwania Capital, Cathay Innovation, Pegatron, and Wistron
Key Investors in Health2Sync
SparkLabs Global Ventures
SparkLabs Global Ventures is a seed-stage fund focused on supporting exceptional entrepreneurs building category-defining companies globally, with a strong emphasis on international scaling and practical mentorship.
iSeed Ventures
iSeed Ventures is a San Francisco-based venture capital firm investing in innovative companies, particularly those leveraging AI technology, and providing strategic support throughout their growth phases.
WI Harper Group
WI Harper Group is a venture capital firm specializing in early-stage investments across healthcare, biotechnology, AI, and sustainability, with a track record of supporting over 250 companies globally.
What's next for Health2Sync?
The recent major strategic investment in Health2Sync signals a pivotal stage for the company, likely indicating a move towards scaling operations, expanding market reach, and further developing its technological capabilities. This enterprise-level funding suggests confidence from investors in Health2Sync's business model and its potential to disrupt the digital therapeutics landscape. Future strategic initiatives may involve deeper integration with healthcare systems, enhanced AI-driven personalization, and broader adoption of its platform for managing a wider range of chronic conditions. The company is poised for significant growth, leveraging this capital to solidify its position as a leader in personalized digital healthcare solutions.
See full Health2Sync company page
